European Journal of Biomedical and Pharmaceutical Sciences

COMPARISON BETWEEN HALOPERIDOL AND RISPERIDONE IN DEVELOPMENT OF METABOLIC SYNDROME IN INDIAN PATIENTS

Chaitanya Patel* Praveen Kumar Vodala, Bellanirys Acosta Arias, Abdul Hanan, Francois Antoine Jr. Legagneur, Beenish Sohail Bhutta

ABSTRACT

Introduction: It is well known that anti-psychotics are associated with many side effects. One of the significant adverse drug reactions among these is weight gain and development of metabolic syndrome. In this study, we compared the most widely used drugs Haloperidol and Risperidone for development of metabolic syndrome in treatment naïve patients with one episode of Schizophrenia. Methods: We took a total of 45 patients who were diagnosed to have Schizophrenia. All these patients never took any anti-psychotic in their live, nor did they take any other medicine for CNS/Psychiatry disorder. Among these 45 patients, 16 patients were put on Haloperidol and 29 patients were prescribed Risperidone. Patients with endocrine disturbances, any systemic disorders, etc. were removed from the study. The baseline characteristics of all the patients were properly studied and recorded. The characteristics were recorded again after 6 months and comparison was done by statistical methods. Results: PANSS score showed a decrease in both groups, systolic blood pressure showed an increase with Haloperidol and an initial decrease with risperidone while diastolic blood pressure increased with haloperidol. Weight gain, increase in waist circumference, rise in triglyceride levels and fall in HDL cholesterol were equally observed in both groups. Increase in plasma glucose was seen more with risperidone (93.1%). 18.86% (n = 10) developed metabolic syndrome at the end of 6months with no difference in emergence between both groups. Conclusion: Risperidone is considered equivalent to Haloperidol in efficacy but it is associated with increase in the components of metabolic syndrome.

Keywords: It is well known Risperidone metabolic syndrome.